A Study of the Effectiveness and Safety of Ofatumumab Compared to Teriflunomide for the Treatment of Patients with Relapsing Multiple Sclerosis


About this study

The purpose of this study is to compare the effectiveness and safety of ofatumumab given by injection every 4 weeks, compared to teriflunomide given orally once daily to patients who have relapsing type (returns and worsens unpredictably) multiple sclerosis.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Diagnosis of multiple sclerosis (MS) 
  • Relapsing MS (RRMS or SPMS) course 
  • At least 1 relapse during the previous 1 year, 2 relapses during the previous 2 years, or a positive gadolinium-enhancing MRI scan in previous year 
  • EDSS score of 0 to 5.5

Exclusion Criteria

  • Primary progressive MS
  • Disease duration of more than 10 years, with an EDSS score of 2 or less 
  • An active chronic disease of the immune system other than MS
  • At risk of developing or having a reactivation of hepatitis 
  • Active systemic infections or neurological findings consistent with PML
  • Other protocol-defined inclusion/exclusion criteria may apply

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Jonathan Carter, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer